Polypill Strategy Boosts Heart Function in Underserved HF Patients: POLY-HF Trial

Introduction

Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality worldwide. Despite robust evidence supporting guideline-directed medical therapy (GDMT), real-world utilization remains suboptimal, particularly among underserved populations. The POLY-HF trial, published in Nature Medicine, tested whether a fixed-dose combination polypill could improve cardiac function and adherence compared to enhanced usual care.

Trial Design and Population

POLY-HF was an open-label, randomized trial conducted at two centers in the United States. Investigators enrolled 212 adults with HFrEF (left ventricular ejection fraction ≤40%), with a median age of 54 years. The study population was predominantly underserved: 22% female, 54% Black, and a high proportion from socioeconomically disadvantaged backgrounds. Participants were randomized 1:1 to receive either a once-daily polypill containing metoprolol succinate (25–150 mg), spironolactone 12.5 mg, and empagliflozin 10 mg, or rapid uptitration of individual GDMT components (enhanced usual care). All participants continued a renin-angiotensin system inhibitor or sacubitril/valsartan as a separate pill.

Primary Endpoint: Ejection Fraction Improvement

The primary endpoint was change in left ventricular ejection fraction (LVEF) assessed by cardiac magnetic resonance imaging at 6 months. In the modified intention-to-treat analysis of 187 participants with follow-up imaging, the polypill group showed a significantly greater improvement in LVEF compared to the enhanced usual care group. The between-group difference was 3.3 percentage points (95% CI, 0.2–6.4; P = 0.039), meeting the primary outcome. This improvement was clinically meaningful, as each 5% increase in LVEF is associated with reduced mortality and heart failure hospitalizations.

Secondary Endpoints: Clinical Outcomes and Adherence

Secondary endpoints included heart failure hospitalizations or emergency department visits and medication adherence. The polypill group experienced a 60% lower rate of heart failure hospitalizations or ED visits (adjusted rate ratio, 0.40; 95% CI, 0.18–0.88; P = 0.024). Adherence, objectively measured by blood concentrations of metoprolol and spironolactone, was significantly higher in the polypill arm: 79% versus 54% in the enhanced usual care group (P = 0.001). The polypill was well tolerated, with fewer adverse events reported compared to enhanced usual care.

Implications for Clinical Practice

The POLY-HF trial demonstrates that a polypill strategy can effectively improve cardiac function and reduce hospitalizations in a challenging real-world population. By simplifying the medication regimen, the polypill addresses key barriers to GDMT adherence, including pill burden, cost, and complexity. These findings are particularly relevant for underserved populations, who often face disparities in heart failure outcomes. The results support the use of polypill-based approaches to close the gap between evidence and practice.

Limitations and Future Directions

The open-label design and relatively small sample size are limitations. The trial was conducted at two centers, and the results may not be generalizable to all settings. Longer follow-up is needed to assess durability of benefits and impact on mortality. Future studies should evaluate the polypill in larger, more diverse populations and explore implementation strategies in routine care.

Conclusion

The POLY-HF trial provides compelling evidence that a once-daily polypill containing metoprolol, spironolactone, and empagliflozin improves ejection fraction, reduces heart failure events, and enhances adherence compared to enhanced usual care. This strategy offers a practical solution to improve outcomes in patients with HFrEF, especially in underserved communities where GDMT utilization is low.

This article is based on reporting by Nature Medicine. Read the original article.